Endo Sues Noven To Protect The Market For Lidoderm

Law360, New York (June 29, 2012, 5:44 PM ET) -- Endo Pharmaceuticals Inc. hit Noven Pharmaceuticals Inc. with a patent suit in Delaware on Friday over Noven's recent bid for U.S. regulatory approval to make and sell a generic version of the Lidoderm adhesive lidocaine pain patch.

Endo, which has the exclusive right to sell the Lidoderm patch in the U.S., targeted Noven Pharmaceuticals and Noven Therapeutics LLC, saying the submission of an application seeking a green light from the U.S. Food and Drug Administration for a generic version of the Lidoderm patch infringes a patent...
To view the full article, register now.